Advaxis, Inc. Cancer Immunotherapy Featured On CNN
3/3/2014 8:51:43 AM
PRINCETON, N.J., March 3, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that ADXS-cHER2, its proprietary immunotherapy designed to treat women with breast cancer, was featured on CNN in a segment focused on its success in treating dogs with osteosarcoma (bone cancer). The segment includes an interview with Dr. Nicola Mason, Assistant Professor of Medicine and Pathobiology at the University of Pennsylvania School of Veterinary Medicine, who is the principle investigator of the featured study, funded by Advaxis, to evaluate ADXS-cHER2 in companion dogs with bone cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by